<DOC>
	<DOCNO>NCT00157118</DOCNO>
	<brief_summary>The purpose study show Protein C Concentrate safe effective treatment subject congenital protein C deficiency . Depending type treatment require , patient assign one 3 study part : Part 1 treatment acute episode , Part 2 short-term prophylaxis , Part 3 long-term prophylaxis infant age less 6 month .</brief_summary>
	<brief_title>Efficacy Safety Study Protein C Concentrate Subjects With Severe Congenital Protein C Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Protein C Deficiency</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Newborn subject &lt; = 6 month age : diagnosis severe congenital protein C deficiency , document functional protein C level &lt; 20 % . If genetic diagnosis available prior initiation Protein C Concentrate treatment , document family history protein C deficiency require . Subjects &gt; 6 month age : confirm diagnosis severe congenital protein C deficiency , i.e. , genetic analysis severe congenital protein C deficiency ( i.e. , homozygous double heterozygous ) OR document family history protein C deficiency AND document functional protein C level &lt; 20 % subject asymptomatic state receive oral anticoagulation therapy Signed date informed consent either subject subject 's legally authorize representative prior enrollment . Informed consent include consent conduct genetic analysis ( genetic defect unknown ) . Subjects history allergic reaction Protein C Concentrate . In case allergic reaction occur Protein C Concentrate injection site ; exclusion study discretion investigator report AE regardless subject 's inclusion exclusion study . Participation clinical study another investigational agent use within 30 day prior enrollment use expect time duration study participation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Severe congenital protein C deficiency</keyword>
</DOC>